Literature DB >> 23325911

Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers.

David Okai1, Sally Askey-Jones, Michael Samuel, Sean S O'Sullivan, K Ray Chaudhuri, Anne Martin, Joel Mack, Richard G Brown, Anthony S David.   

Abstract

OBJECTIVE: To test the effects of a novel cognitive-behavioral therapy (CBT)-based intervention delivered by a nurse therapist to patients with Parkinson disease (PD) with clinically significant impulse control behaviors (ICB).
METHODS: This was a randomized controlled trial comparing up to 12 sessions of a CBT-based intervention compared to a waiting list control condition with standard medical care (SMC). A total of 27 patients were randomized to the intervention and 17 to the waiting list. Patients with a Mini-Mental State Examination score of <24 were excluded. The coprimary outcomes were overall symptom severity and neuropsychiatric disturbances in the patients and carer burden and distress after 6 months. Secondary outcome measures included depression and anxiety, marital satisfaction, and work and social adjustment in patients plus general psychiatric morbidity and marital satisfaction in carers.
RESULTS: There was a significant improvement in global symptom severity in the CBT intervention group vs controls, from a mean score consistent with moderate to one of mild illness-related symptoms (χ(2) = 16.46, p < 0.001). Neuropsychiatric disturbances also improved significantly (p = 0.03), as did levels of anxiety and depression and adjustment. Measures of carer burden and distress showed changes in the desired direction in the intervention group but did not change significantly. General psychiatric morbidity did improve significantly in the carers of patients given CBT.
CONCLUSIONS: This CBT-based intervention is the first to show efficacy in ICB related to PD in terms of patient outcomes. The hoped-for alleviation of carer burden was not observed. The study demonstrates the feasibility and potential benefit of a psychosocial treatment approach for these disturbances at least in the short term, and encourages further larger-scale clinical trials. CLASSIFICATION OF EVIDENCE: The study provides Class IV evidence that CBT plus SMC is more effective than SMC alone in reducing the severity of ICB in PD, based upon Clinical Global Impression assessment (χ(2) = 16.46, p < 0.001): baseline to 6-month follow-up, reduction in symptom severity CBT group, 4.0-2.5; SMC alone group, 3.7-3.5.

Entities:  

Mesh:

Year:  2013        PMID: 23325911      PMCID: PMC3598451          DOI: 10.1212/WNL.0b013e3182840678

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992.

Authors:  A J Hughes; Y Ben-Shlomo; S E Daniel; A J Lees
Journal:  Neurology       Date:  2001-11       Impact factor: 9.910

2.  The effect of compliance-improving interventions on the cognitive-behavioural treatment of pathological gambling.

Authors:  Simon Milton; Rocco Crino; Caroline Hunt; Emma Prosser
Journal:  J Gambl Stud       Date:  2002

3.  Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination.

Authors:  D W Molloy; E Alemayehu; R Roberts
Journal:  Am J Psychiatry       Date:  1991-01       Impact factor: 18.112

4.  Subjective burden of husbands and wives as caregivers: a longitudinal study.

Authors:  S H Zarit; P A Todd; J M Zarit
Journal:  Gerontologist       Date:  1986-06

5.  A scaled version of the General Health Questionnaire.

Authors:  D P Goldberg; V F Hillier
Journal:  Psychol Med       Date:  1979-02       Impact factor: 7.723

6.  The Work and Social Adjustment Scale: a simple measure of impairment in functioning.

Authors:  James C Mundt; Isaac M Marks; M Katherine Shear; John H Greist
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

7.  Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.

Authors:  G Giovannoni; J D O'Sullivan; K Turner; A J Manson; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

8.  Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.

Authors:  Andrew H Evans; Regina Katzenschlager; Dominic Paviour; John D O'Sullivan; Silke Appel; Andrew D Lawrence; Andrew J Lees
Journal:  Mov Disord       Date:  2004-04       Impact factor: 10.338

Review 9.  Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?

Authors:  Andrew D Lawrence; Andrew H Evans; Andrew J Lees
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

10.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

View more
  35 in total

Review 1.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 2.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 3.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

4.  Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.

Authors:  Jacob Taylor; William S Anderson; Jason Brandt; Zoltan Mari; Gregory M Pontone
Journal:  Am J Geriatr Psychiatry       Date:  2016-09-03       Impact factor: 4.105

Review 5.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 6.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

8.  Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Authors:  Kimberly Papay; Sharon X Xie; Matthew Stern; Howard Hurtig; Andrew Siderowf; John E Duda; James Minger; Daniel Weintraub
Journal:  Neurology       Date:  2014-07-18       Impact factor: 9.910

9.  Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-09

Review 10.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.